Amlitelimab PK Simulator
Indication: Atopic Dermatitis
Population PK simulator for amlitelimab anti-OX40L antibody. Explore dosing regimens in atopic dermatitis.
Drug Overview
Clinical Context
- Molecular Target
- OX40L
- Drug Class
- mAb
- Therapeutic Area
- Immunology
- Indication
- Atopic Dermatitis
- Route of Administration
- SC/IV
Model Information
- Model Type
- PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| Q | 0.5-0.8 L/day |
| Vc | 3-4 L |
| Vp | 2-3 L |
| t half | ~20 days |
| CL linear | 0.15-0.25 L/day |
| bioavailability SC | 0.6-0.7 |
Additional Parameters
| Parameter | Value |
|---|---|
| dose | 250 mg SC q4w (after loading) |
| ka SC | 0.2-0.3 day⁻¹ |
| IIV CL | 30-40% CV |
| target | OX40 ligand |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Amlitelimab allows you to explore concentration-time profiles under different dosing scenarios. The underlying PopPK model characterizes the pharmacokinetics of this mab following sc/iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Amlitelimab PK simulator?
This is a free, interactive pharmacokinetic simulator for Amlitelimab used in Atopic Dermatitis. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Amlitelimab belong to?
Amlitelimab is classified as a mAb that targets OX40L. It is used in the Immunology therapeutic area.
What route of administration does this model simulate?
This simulator models SC/IV administration of Amlitelimab. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Amlitelimab?
Based on the published model parameters, the elimination half-life of Amlitelimab is approximately ~20 days. Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of Amlitelimab?
The clearance (CL) of Amlitelimab is approximately 0.15-0.25 L/day. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Related Simulators
Xolair (Omalizumab) PK Simulator
Moderate-to-severe allergic asthma
Tremfya (Guselkumab) PK Simulator
Plaque psoriasis
Tecentriq (Atezolizumab) PK Simulator
Non-small cell lung cancer
Stelara (Ustekinumab) PK Simulator
Plaque psoriasis
Skyrizi (Risankizumab) PK Simulator
Plaque psoriasis
Rinvoq (Upadacitinib) PK Simulator
Rheumatoid arthritis
Ready to Simulate?
Launch the Amlitelimab simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community